Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 6/20 | 0.42 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | PRKAB2 | O43741 | 3/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 3/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 3/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 3/20 | 0.38 |
| ▸ | PRKAG3 | Q9UGI9 | 3/20 | 0.38 |
| ▸ | PRKAG2 | Q9UGJ0 | 3/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 3/20 | 0.38 |
| ▸ | NAPEPLD | Q6IQ20 | 7/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21996816 | 1.00 | SMPD3 (0.42) | SMPD3APOBEC3AAPOBEC3GPRKDCPRKAB2 | |
| SCHEMBL21997705 | 0.93 | SMPD3 (0.47) | SMPD3APOBEC3AAPOBEC3GPRKAB2PRKAG1 | |
| SCHEMBL21997071 | 0.90 | APOBEC3A (0.44) | SMPD3APOBEC3AAPOBEC3GCYP2D6DPP4 | |
| SCHEMBL25338105 | 0.82 | APOBEC3A (0.47) | SMPD3APOBEC3AAPOBEC3G | |
| SCHEMBL25339261 | 0.82 | APOBEC3A (0.47) | SMPD3APOBEC3AAPOBEC3G | |
| SCHEMBL21997579 | 0.81 | L3MBTL3 (0.40) | SMPD3APOBEC3AAPOBEC3GNAPEPLD | |
| SCHEMBL21996782 | 0.81 | APOBEC3A (0.46) | SMPD3APOBEC3AAPOBEC3G | |
| SCHEMBL21997059 | 0.81 | APOBEC3A (0.41) | APOBEC3AAPOBEC3GCYP2D6DPP4KCNH2 | |
| SCHEMBL25338043 | 0.79 | NR3C2 (0.42) | APOBEC3AAPOBEC3G | |
| SCHEMBL21997412 | 0.79 | APOBEC3A (0.42) | SMPD3APOBEC3AAPOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3886904-A1 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2021-10-06 | — | — | EP | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2020113233-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-20240239777-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | SMPD3 2865/4885APOBEC3A 219/4885APOBEC3G 151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.